Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A Convenient Way to Screen Hydrogel Stiffness for Stem Cell Applications

Published: Tuesday, August 28, 2012
Last Updated: Tuesday, August 28, 2012
Bookmark and Share
BioTime, Inc. announce the debut of their new Glycosan-branded hydrogel kit for screening the stiffness requirements for growing 3D cell cultures.

Research has shown that in addition to induction factors, the rigidity of the substrate on which cells are grown has a significant influence in the lineage specificity of the cell. By mimicking the cell’s in-vivo environment on a petri dish, the cell has a greater affinity to differentiate into specific cell lines.

glycosan.gifThe HyStem-C Stiffness Sampler Trio Kit contains hyaluronan-based, synthetic extracellular matrices that can conveniently screen for the perfect in-vitro environment for stem cells to proliferate.  The kit contains three hydrogels of defined stiffness to take the guesswork out of choosing the right rigidity.  Like its predecessors, the gels are biocompatible, customizable, and allows for attachment of multiple cell types. The hydrogel is easily prepared by mixing the gel and water (both included in the kit) together. Then the cells are either plated on top or encapsulated in the gel. Current applications include vascular morphogenesis, neurogenesis, and other soft tissue cell cultures. For more information, please visit Glycosan’s website at www.glycosan.com.

BioTime, Inc. is a biotechnology company focused on regenerative medicine. The company develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary ReCyte Therapeutics, Inc. The company engages in two areas of biomedical research and product development. Its focus is in the field of regenerative medicine; specifically human embryonic stem cell and induced pluripotent stem cell technology. BioTime was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OncoCyte and Abcodia to Collaborate on Breast Cancer Diagnostic Development
PanC-Dx™ markers to be validated using pre-diagnosis patient serum samples exclusively provided by Abcodia.
Tuesday, September 16, 2014
BioTime Completes Merger of XenneX, Inc. into LifeMap Sciences, Inc.
LifeMap Sciences now holds the exclusive, worldwide licenses to market GeneCards(R) and PanDaTox from Yeda Research and Development Company Ltd.
Monday, May 21, 2012
BioTime to Produce Stem Cells for Research in Muscle Disorders
The company announced that it has elected to market progenitors of muscle stem cells bearing hereditary diseases and will produce the products from five human embryonic stem (hES) cell lines from Reproductive Genetics Institute (RGI).
Tuesday, January 03, 2012
BioTime Announces Appointment of Chief Financial Officer
Peter Garcia will lead the accounting, finance and investor relations functions of the Company, reporting directly to Michael D. West, Ph.D., President and CEO.
Monday, October 10, 2011
BioTime and Embryome Sciences Launch Embryome.com and the International Embryome Initiative
The international collaboration with scientists around the world will create the first systematic map of all the cell types derived from human embryonic stem cells.
Monday, June 30, 2008
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Defining Immortality of Stem Cells
Researchers defined the mechanisms underlying increased protein quality control of pluripotent stem cells.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Stem Cells Police Themselves to Reduce Scarring
Scientists have discovered stem cells in muscle fibers change gene expressions to respond to injury.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
Topical Immunotherapy Effective Against Early Skin Cancer
Combination of two commonly used drugs triggers immune response against precancerous skin lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!